[原发性进行性多发性硬化症CD14+单核细胞DNA甲基化谱的变化]。

Q3 Medicine
I S Kiselev, O G Kulakova, O A Baturina, M R Kabilov, A N Boyko, O O Favorova
{"title":"[原发性进行性多发性硬化症CD14+单核细胞DNA甲基化谱的变化]。","authors":"I S Kiselev,&nbsp;O G Kulakova,&nbsp;O A Baturina,&nbsp;M R Kabilov,&nbsp;A N Boyko,&nbsp;O O Favorova","doi":"10.31857/S002689842305004X, EDN: GVHYAT","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a chronic autoimmune inflammatory and neurodegenerative disease of the central nervous system, which is characterized by significant clinical heterogeneity. Primary progressive MS (PPMS) develops in 10-15% of patients. Unlike the most common relapsing-remitting form of MS, PPMS involves steady progress of neurodegeneration and, as a consequence, a persistent gradual increase in neurological symptoms. The peculiarities of epigenetic regulation of gene expression may be one of the reasons for the differences in the pathogenesis of the two MS forms. DNA methylation is one of the key epigenetic mechanisms, which remains almost unexplored in different cell populations of PPMS patients. The goal of this work was to identify differential methylation profiles of the CpG sites in the CD14+ monocyte DNA, which characterize PPMS. A genome-wide analysis of DNA methylation in PPMS patients and healthy individuals has identified 169 differentially methylated positions (DMPs), 90.5% of which were hypermethylated in PPMS patients. More than half of all DMPs are located in/near known genes and within CpG islands and their neighboring regions, which indicates their high functional significance. We have found six differentially methylated regions (DMRs) in the OR2L13, CAT, LCLAT1, HOXA5, RNF39, and CRTAC1 genes involved in inflammation and neurodegeneration, which indicates active epigenetic regulation of their expression.</p>","PeriodicalId":39818,"journal":{"name":"Molekulyarnaya Biologiya","volume":"57 5","pages":"819-826"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[DNA Methylation Profile of CD14+ Monocytes Changes in Primary Progressive Multiple Sclerosis].\",\"authors\":\"I S Kiselev,&nbsp;O G Kulakova,&nbsp;O A Baturina,&nbsp;M R Kabilov,&nbsp;A N Boyko,&nbsp;O O Favorova\",\"doi\":\"10.31857/S002689842305004X, EDN: GVHYAT\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Multiple sclerosis (MS) is a chronic autoimmune inflammatory and neurodegenerative disease of the central nervous system, which is characterized by significant clinical heterogeneity. Primary progressive MS (PPMS) develops in 10-15% of patients. Unlike the most common relapsing-remitting form of MS, PPMS involves steady progress of neurodegeneration and, as a consequence, a persistent gradual increase in neurological symptoms. The peculiarities of epigenetic regulation of gene expression may be one of the reasons for the differences in the pathogenesis of the two MS forms. DNA methylation is one of the key epigenetic mechanisms, which remains almost unexplored in different cell populations of PPMS patients. The goal of this work was to identify differential methylation profiles of the CpG sites in the CD14+ monocyte DNA, which characterize PPMS. A genome-wide analysis of DNA methylation in PPMS patients and healthy individuals has identified 169 differentially methylated positions (DMPs), 90.5% of which were hypermethylated in PPMS patients. More than half of all DMPs are located in/near known genes and within CpG islands and their neighboring regions, which indicates their high functional significance. We have found six differentially methylated regions (DMRs) in the OR2L13, CAT, LCLAT1, HOXA5, RNF39, and CRTAC1 genes involved in inflammation and neurodegeneration, which indicates active epigenetic regulation of their expression.</p>\",\"PeriodicalId\":39818,\"journal\":{\"name\":\"Molekulyarnaya Biologiya\",\"volume\":\"57 5\",\"pages\":\"819-826\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molekulyarnaya Biologiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31857/S002689842305004X, EDN: GVHYAT\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molekulyarnaya Biologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31857/S002689842305004X, EDN: GVHYAT","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

多发性硬化症(MS)是一种中枢神经系统的慢性自身免疫性炎症和神经退行性疾病,具有显著的临床异质性。10-15%的患者发生原发性进行性多发性硬化症(PPMS)。与最常见的复发-缓解型MS不同,PPMS涉及神经退行性变的稳定进展,因此,神经症状持续逐渐增加。基因表达表观遗传调控的特殊性可能是两种MS发病机制差异的原因之一。DNA甲基化是关键的表观遗传学机制之一,在PPMS患者的不同细胞群体中几乎未被探索。这项工作的目的是鉴定CD14+单核细胞DNA中CpG位点的差异甲基化谱,以表征PPMS。PPMS患者和健康个体DNA甲基化的全基因组分析已确定169个差异甲基化位置(DMP),其中90.5%在PPMS患者中为高甲基化。超过一半的DMP位于已知基因中/附近以及CpG岛及其邻近区域内,这表明它们具有高度的功能意义。我们在OR2L13、CAT、LCLAT1、HOXA5、RNF39和CRTAC1基因中发现了六个参与炎症和神经退行性变的差异甲基化区(DMRs),这表明它们的表达受到了积极的表观遗传学调控。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[DNA Methylation Profile of CD14+ Monocytes Changes in Primary Progressive Multiple Sclerosis].

Multiple sclerosis (MS) is a chronic autoimmune inflammatory and neurodegenerative disease of the central nervous system, which is characterized by significant clinical heterogeneity. Primary progressive MS (PPMS) develops in 10-15% of patients. Unlike the most common relapsing-remitting form of MS, PPMS involves steady progress of neurodegeneration and, as a consequence, a persistent gradual increase in neurological symptoms. The peculiarities of epigenetic regulation of gene expression may be one of the reasons for the differences in the pathogenesis of the two MS forms. DNA methylation is one of the key epigenetic mechanisms, which remains almost unexplored in different cell populations of PPMS patients. The goal of this work was to identify differential methylation profiles of the CpG sites in the CD14+ monocyte DNA, which characterize PPMS. A genome-wide analysis of DNA methylation in PPMS patients and healthy individuals has identified 169 differentially methylated positions (DMPs), 90.5% of which were hypermethylated in PPMS patients. More than half of all DMPs are located in/near known genes and within CpG islands and their neighboring regions, which indicates their high functional significance. We have found six differentially methylated regions (DMRs) in the OR2L13, CAT, LCLAT1, HOXA5, RNF39, and CRTAC1 genes involved in inflammation and neurodegeneration, which indicates active epigenetic regulation of their expression.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molekulyarnaya Biologiya
Molekulyarnaya Biologiya Medicine-Medicine (all)
CiteScore
0.70
自引率
0.00%
发文量
131
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信